Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

D-Cycloserine Enhancement of Exposure-Based CBT for Smoking Cessation (DCSSmoking)

This study has been withdrawn prior to enrollment.
(Study was not funded and pilot work proved impractical.)
Information provided by (Responsible Party):
Michael Otto, Boston University Charles River Campus Identifier:
First received: January 21, 2009
Last updated: April 28, 2017
Last verified: April 2017
This study examines whether isolated doses of D-cycloserine enhance the efficacy of CBT for smoking cessation.

Condition Intervention Phase
Drug: D-cycloserine
Drug: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Participant, Investigator
Primary Purpose: Treatment
Official Title: D-Cycloserine Enhancement of Exposure-Based CBT for Smoking Cessation

Resource links provided by NLM:

Further study details as provided by Boston University Charles River Campus:

Primary Outcome Measures:
  • Carbon monoxide analysis [ Time Frame: Baseline, Weeks 4, 5, 6, 7, 8, 9, 13, 21, & 29 ]
  • Cotinine levels in saliva [ Time Frame: Baseline, Weeks 21 & 29 ]

Secondary Outcome Measures:
  • Anxiety Sensitivity Index [ Time Frame: Baseline, Weeks 5, 6, 7, 8, 9, 13, 21 & 29 ]
  • Minnesota Withdrawal Scale [ Time Frame: Each visit ]
  • Mood & Anxiety Symptom Questionnaire [ Time Frame: Baseline, Weeks 1, 2, 3, 4, 5, 6, 7, & 8 ]
  • Smoking Cessation Self-Efficacy [ Time Frame: Baseline, Weeks 3, 4, 5, 6, 7, 8, 9, 13, 21 & 29 ]

Enrollment: 0
Actual Study Start Date: August 2008
Study Completion Date: July 15, 2015
Primary Completion Date: July 15, 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
DCS-augmented CBT for smoking cessation
Drug: D-cycloserine
Single dosage prior to sessions 3, 4 & 5
Other Name: DCS
Placebo Comparator: 2
Placebo-augmented CBT for smoking cessation
Drug: Placebo
Single dosage prior to sessions 3, 4 & 5

Detailed Description:
In comparison to placebo-augmented cognitive behavioral therapy (CBT), D-cycloserine-augmented CBT will lead to a greater reduction in both short-and long-term point prevalence abstinence as well as time to first smoking lapse and time to smoking relapse.

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

1. Be a regular smoker for at least one year 3. Currently smoke an average of at least 10 cigarettes per day 4. Report a motivation to quit smoking in the next month of at least 5 on a 10 point scale 5. Score 20 or greater on the 16-item Anxiety Sensitivity Index (Schmidt & Joiner, 2002).

Exclusion Criteria:

  1. Current diagnosis of a psychotic, eating, developmental or bipolar disorder (as determined by the SCID)
  2. Current anxiety or mood disorder rated moderate or greater (i.e., CGI score of 4 or greater for an anxiety or depressive disorder or any current or recent—1 year--suicidal ideation)
  3. Psychoactive substance abuse or dependence (excluding nicotine dependence) within the past 6 months
  4. Current use of isoniazid psychotropic medication
  5. A history of significant medical condition, such as cardiovascular, neurologic, gastrointestinal, pregnancy and/or breast feeding, history of seizure (other than febrile seizures in childhood) or other systemic illness and/or be deemed as currently unhealthy in the context of a complete physical examination
  6. Limited mental competency and the inability to give informed, voluntary, written consent to participate,
  7. Current use of any pharmacotherapy or psychotherapy for smoking cessation not provided by the researchers during the quit attempt,
  8. Concurrent psychotherapy initiated within three months of baseline, or ongoing psychotherapy of any duration directed specifically toward treatment of anxiety or mood disorder other than general supportive therapy initiated at least 3 months prior to the study
  9. Use of other tobacco products
  10. Planning on moving (outside of the immediate area) in the next six months
  11. Insufficient command of the English language (i.e., they cannot carry on a conversation with an interviewer in the English language or read associated text).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00827281

United States, Massachusetts
Boston University
Boston, Massachusetts, United States, 02215
Sponsors and Collaborators
Boston University Charles River Campus
  More Information

Responsible Party: Michael Otto, Ph.D., Boston University Charles River Campus Identifier: NCT00827281     History of Changes
Other Study ID Numbers: 1728
Study First Received: January 21, 2009
Last Updated: April 28, 2017

Keywords provided by Boston University Charles River Campus:

Additional relevant MeSH terms:
Anti-Infective Agents, Urinary
Anti-Infective Agents
Renal Agents
Antibiotics, Antitubercular
Antitubercular Agents
Anti-Bacterial Agents
Molecular Mechanisms of Pharmacological Action processed this record on May 22, 2017